[ENZY] Enzymotec Ltd.

Overview

Type of security: Stock

Sector: Consumer Durables

Industry: Specialty Chemicals

Market Capitalization: 196.07 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 6.65 Change: 0.25 (3.91%)
Ext. hours: Change: 0 (0%)

chart ENZY

Refresh chart

Description: Enzymotec Ltd., together with its subsidiaries, develops, manufactures, markets, and sells bio-functional lipid ingredients and final products in North America, Europe, Asia, Australia, New Zealand, and Israel. The company?s Nutrition segment develops and manufactures nutritional ingredient products based on lipids, such as phospholipids, which form the structural basis of cell membranes. Its products include InFat, a lipid ingredient for infant formula that resembles the composition and properties of human breast milk fat; Soy-PS, a lipid ingredient for infant formula that improves cognitive and mental performance; and Krill Oil, an omega-3 bound to phospholipids. It also offers phosphatidylserine (PS) products, including Sharp PS, a nutritional supplement for adults to improve cognitive capabilities; and Sharp PS SILVER, a blend of two active ingredients comprising PS and omega-3 to improve mental and cognitive abilities. In addition, this segment provides Sharp PS GOLD, a compound nutrient for improving me

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding22.72 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-44.6 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities60 K Cash From Investing Activities-920 K Cash From Operating Activities3.15 M Gross Profit7 M
Net Profit1.74 M Operating Profit1.65 M Total Assets142.27 M Total Current Assets76.12 M
Total Current Liabilities10.03 M Total Debt Total Liabilities11.19 M Total Revenue11.3 M
Technical Data
High 52 week11.95 Low 52 week6.45 Last close11.85 Last change-0.21%
RSI50 Average true range0.06 Beta0.56 Volume14.12 K
Simple moving average 20 days0.08% Simple moving average 50 days0.25% Simple moving average 200 days18.81%
Performance Data
Performance Week0.42% Performance Month0% Performance Quart6.76% Performance Half58%
Performance Year53.9% Performance Year-to-date0% Volatility daily0.33% Volatility weekly0.74%
Volatility monthly1.52% Volatility yearly5.27% Relative Volume28.2% Average Volume154.15 K
New High New Low

News

2018-01-01 09:09:32 | Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

2017-12-12 02:41:32 | Merger Deal between Enzymotec and Frutarom Approved by 99.9% Majority of Enzymotec Shareholders

2017-12-11 17:15:00 | Enzymotec Shareholders Approve Proposed Acquisition by Frutarom

2017-11-15 07:40:39 | Enzymotec posts 3Q profit

2017-11-15 07:35:00 | Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results

2017-11-02 08:15:00 | Enzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other Matters

2017-10-29 04:10:47 | Israeli flavour firm Frutarom to buy remaining 81 pct of Enzymotec

2017-10-29 02:03:47 | Frutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210M

2017-10-29 00:00:00 | Enzymotec Enters Definitive Agreement to be Acquired by Frutarom

2017-10-05 09:37:03 | Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017

2017-08-30 08:30:00 | Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare

2017-08-28 08:30:00 | Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd.

2017-08-28 07:30:00 | Corporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives

2017-08-24 02:43:03 | Frutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% Stake in Enzymotec

2017-08-16 22:45:01 | Enzymotec reports 2Q loss

2017-08-16 07:30:00 | Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results

2017-08-16 06:50:00 | Investor Network: Enzymotec Ltd. to Host Earnings Call

2017-07-28 08:30:00 | Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer

2017-07-26 08:30:00 | Enzymotec to Report Second Quarter 2017 Financial Results

2017-06-28 08:30:00 | Enzymotec Chief Financial Officer to Step Down

2017-06-14 09:23:17 | Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017

2017-06-13 09:00:01 | Weakness Seen in Enzymotec ENZY Estimates: Should You Stay Away?

2017-06-06 08:30:00 | Enzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold

2017-05-25 08:30:00 | Enzymotec Ltd. to Present at the Jefferies 2017 Global Healthcare Conference

2017-05-17 07:42:44 | Enzymotec misses 1Q profit forecasts

2017-05-17 07:30:00 | Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results

2017-05-17 07:00:00 | Investor Network: Enzymotec Ltd. to Host Earnings Call

2017-05-03 08:30:00 | Enzymotec to Report First Quarter 2017 Financial Results

2017-05-02 08:30:00 | VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods

2017-04-03 09:22:51 | Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q4, 2016 By the Numbers : April 3, 2017

2017-04-03 08:15:00 | Neptune and Enzymotec Reach Patent Agreement Ending All Litigation

2017-04-03 08:00:00 | Neptune and Enzymotec reach Patent Agreement Ending All Litigation

2017-03-16 08:30:00 | Enzymotec Files Annual Report on Form 20-F for the Year Ended December 31, 2016

2017-03-10 08:30:00 | Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders

2017-03-09 08:30:00 | Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO

2017-02-22 08:05:49 | Enzymotec reports 4Q loss

2017-02-22 07:30:00 | Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results

2017-02-06 08:30:00 | Enzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results

2016-12-21 03:12:14 | 2016-12-21 Enzymatica AB: Top-line results of new clinical trial

2016-12-19 10:41:16 | 2016-12-19 Enzymatica AB: Bulletin from extraordinary general meeting in Enzymatica AB publ

2016-12-15 20:01:08 | Does Enzymotec Ltd ENZY Stack Up To Its Peers In This Metric?

2016-12-12 09:48:02 | What Makes Enzymotec ENZY a Strong Sell?

2016-12-01 10:21:57 | 2016-12-01 Enzymatica AB: Extraordinary shareholders' meeting on changes to the board of directors

2016-12-01 10:21:55 | 2016-12-01 Enzymatica AB: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB publ

2016-11-28 10:32:06 | Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016

2016-11-17 07:18:51 | Enzymotec downgraded by Wells Fargo

2016-11-16 12:18:41 | Edited Transcript of ENZY earnings conference call or presentation 16-Nov-16 1:30pm GMT

2016-11-16 08:18:08 | Enzymotec Ltd. Announces Departure of its CEO

2016-11-16 07:44:43 | Enzymotec reports 3Q loss

2016-11-16 07:30:00 | Enzymotec Ltd. Announces Departure of its CEO